Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have shown some efficacy in patients with CNS metastases from an EGFR‐mutant lung cancer (Economopoulou and Mountzios, 2016; Park et al., 2012; Wu et al., 2013). This evidence concerns the gene EGFR and lung carcinoma.